Our findings indicate that high levels of METTL10 expression may serve as a diagnostic marker for advanced, progressive forms of GC, particularly in refractory GC (RGC), which shows poor responses to standard treatments and experiences frequent relapses within short timeframes. Here, EEF1AKMT2 is linked to gastric cancer.